Boston Scientific Closes Acquisition of Axonics, Inc.

$AXNX
$BSX
Medical/Dental Instruments
Health Care
Medical/Dental Instruments
Health Care
Get the next $AXNX alert in real time by email

MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.

"Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisition, we're pleased to welcome the Axonics team into Boston Scientific. The addition of the Axonics product portfolio enables us to expand into sacral neuromodulation, a high-growth adjacency for our Urology business, while bringing a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity."

The purchase price of $71 cash per share represents an equity value of $3.7 billion and an enterprise value of $3.3 billion.1 The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges.

Additional information about this transaction is available on the Events and Presentations section of the Boston Scientific investor relations website.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the financial and business impact of the transaction and anticipated benefits of the transaction, our business plans and strategy, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; demographic trends; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the transaction and successfully integrate Axonics' operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the transaction; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS:

Nate Gilbraith

Media Relations

+1 (701) 212-9589

nate.gilbraith@bsci.com

Jon Monson

Investor Relations

+1 (508) 683-5450

BSXInvestorRelations@bsci.com

1 Equity value based on total fully diluted share count of approximately 51.7 million shares including management incentives; Enterprise value is equal to Equity value minus net cash and short-term investments of approximately $0.4 billion as of September 30, 2024.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-closes-acquisition-of-axonics-inc-302307088.html

SOURCE Boston Scientific Corporation

Get the next $AXNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AXNX
$BSX

CompanyDatePrice TargetRatingAnalyst
1/10/2025$108.00Hold → Buy
Deutsche Bank
10/18/2024Buy → Hold
Needham
5/30/2024$90.00Buy
Goldman
2/1/2024$65.00 → $80.00Neutral → Buy
Mizuho
1/9/2024Outperform → Peer Perform
Wolfe Research
7/19/2023$59.00Outperform
Robert W. Baird
7/19/2023$69.00Outperform
Robert W. Baird
7/13/2023$70.00Overweight
KeyBanc Capital Markets
More analyst ratings

$AXNX
$BSX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Boston Scientific announces agreement to acquire SoniVie Ltd.

    Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.

    $BSX
    Medical/Dental Instruments
    Health Care
  • Boston Scientific announces completion of €1.5 billion offering of senior notes

    MARLBOROUGH, Mass., Feb. 26, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has completed a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000,000 aggregate principal amount of 3.250% notes due 2034 (collectively, the "Notes"). The Notes are fully and unconditionally guaranteed by the Company. Application has been made for the Notes to be admitted to the Official List of the Irish Stock Exchange plc trading as Euronext Dublin and to trading on the Global Exchange Market thereof.

    $BSX
    Medical/Dental Instruments
    Health Care
  • Boston Scientific announces pricing of €1.5 billion of senior notes

    MARLBOROUGH, Mass., Feb. 21, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has priced a public offering of €850,000,000 aggregate principal amount of 3.000% notes due 2031 and €650,000,000 aggregate principal amount of 3.250% notes due 2034 (collectively, the "Notes"). The Notes will be fully and unconditionally guaranteed by the Company. The offering is being made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission. 

    $BSX
    Medical/Dental Instruments
    Health Care

$AXNX
$BSX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AXNX
$BSX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$AXNX
$BSX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AXNX
$BSX
SEC Filings

See more

$AXNX
$BSX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    $BSX
    Medical/Dental Instruments
    Health Care

$AXNX
$BSX
Leadership Updates

Live Leadership Updates

See more
  • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

    BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

    $BSX
    Medical/Dental Instruments
    Health Care
  • SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

    TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi

    $BSX
    Medical/Dental Instruments
    Health Care
  • Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

    Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer

    $AXNX
    Medical/Dental Instruments
    Health Care

$AXNX
$BSX
Financials

Live finance-specific insights

See more
  • Boston Scientific announces results for fourth quarter and full year 2024

    MARLBOROUGH, Mass., Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.34 per share a year ago and achieved adjusted3 EPS of $0.70 for the period, compared to $0.55 a year ago.

    $BSX
    Medical/Dental Instruments
    Health Care
  • Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results

    MARLBOROUGH, Mass., Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief executive officer, will present at approximately 5:15 p.m. PT / 8:15 p.m. ET. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Kenneth Stein, M.D., senior vice president and chief medical officer, in a question-and-answer session with the host analyst. Additionally, the company will webcast its

    $BSX
    Medical/Dental Instruments
    Health Care
  • Boston Scientific Announces Results for Third Quarter 2024

    MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

    $BSX
    $SILK
    Medical/Dental Instruments
    Health Care

$AXNX
$BSX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more